Handelsbanken Fonder AB Decreases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Handelsbanken Fonder AB decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 19,400 shares of the medical equipment provider’s stock after selling 700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Lantheus were worth $1,736,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new stake in Lantheus in the fourth quarter valued at approximately $27,000. Signaturefd LLC lifted its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the last quarter. UMB Bank n.a. lifted its stake in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC purchased a new stake in Lantheus in the third quarter valued at approximately $60,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

LNTH has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Price Performance

Lantheus stock opened at $80.07 on Wednesday. Lantheus Holdings, Inc. has a 12 month low of $56.44 and a 12 month high of $126.89. The business has a 50 day simple moving average of $89.77 and a 200-day simple moving average of $96.81. The stock has a market capitalization of $5.57 billion, a PE ratio of 13.32 and a beta of 0.44.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.